Steven Arkin

4.4k citations

53 papers · 2.5k indexed · h-index 24

Impact in

Hematology top 0.5%
- Hemophilia Treatment and Research
- Platelet Disorders and Treatments
- Blood Coagulation and Thrombosis Mechanisms
- Chronic Myeloid Leukemia Treatments
- Hemostasis and retained surgical items
Genetics top 1%
- Chronic Lymphocytic Leukemia Research
- Coagulation, Bradykinin, Polyphosphates, and Angioedema

Papers in ⓘ

Hematology 40
- Hemophilia Treatment and Research 30
- Chronic Myeloid Leukemia Treatments 11
- Blood Coagulation and Thrombosis Mechanisms 10
- Platelet Disorders and Treatments 9
Genetics 15
- Chronic Lymphocytic Leukemia Research 7
- Coagulation, Bradykinin, Polyphosphates, and Angioedema 4

Co-authors: Jeanne M. Lusher (6 shared papers)Richard S. Schwartz (3 shared papers)Charles F. Abildgaard (2 shared papers)Jörge E. Cortes (5 shared papers)Carlo Gambacorti‐Passerini (5 shared papers)H. Jean Khoury (4 shared papers)Hagop M. Kantarjian (3 shared papers)Anna Turkina (3 shared papers)
Journals: Blood (16 papers)Haemophilia (4 papers)Journal of Thrombosis and Haemostasis (4 papers)British Journal of Haematology (3 papers)Journal of Clinical Oncology (2 papers)
Partner nations: United States Italy Poland

In The Last Decade

Steven Arkin

51 papers receiving 2.4k citations

Peers

Countries citing papers authored by Steven Arkin

Since Specialization

Citations

This map shows the geographic impact of Steven Arkin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven Arkin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven Arkin more than expected).

Fields of papers citing papers by Steven Arkin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven Arkin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven Arkin. The network helps show where Steven Arkin may publish in the future.

Co-authors

The 25 scholars most cited alongside Steven Arkin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Steven Arkin Line = papers co-authored together Steven Arkin links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 53 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Recombinant Factor VIII for the Treatment of Previously Untreated Patients with Hemophilia A -- Safety, Efficacy, and Development of Inhibitors New England Journal of Medicine ·Jeanne M. Lusher, Steven Arkin, Charles F. Abildgaard, Richard S. Schwartz	1993	373
2	Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinib Blood ·Jörge E. Cortes, Hagop M. Kantarjian, Tim H. Brümmendorf, Dong‐Wook Kim, Anna Turkina, Zhi-Xiang Shen, Ricardo Pasqüini, H. Jean Khoury, Steven Arkin, Angela Volkert, Nadine Besson, Richat Abbas, Junyuan Wang, Eric Leip, Carlo Gambacorti‐Passerini	2011	348
3	Assessment and Reporting of the Clinical Immunogenicity of Therapeutic Proteins and Peptides—Harmonized Terminology and Tactical Recommendations The AAPS Journal ·Ganesh M. Shankar, Steven Arkin, Laurent Cocea, Viswanath Devanarayan, Susan Kirshner, Arno Kromminga, Valerie Quarmby, S Richards, Christian K. Schneider, Meena Subramanyam, Steven J. Swanson, Daniela Verthelyi, Samantha S. Yim	2014	236
4	Human Recombinant DNA–Derived Antihemophilic Factor (Factor VIII) in the Treatment of Hemophilia A New England Journal of Medicine ·Richard S. Schwartz, Charles F. Abildgaard, Louis M. Aledort, Steven Arkin, A. L. Bloom, H.‐H. Brackmann, Doreen B. Brettler, Hiromu Fukui, Margaret W. Hilgartner, Martin J. Inwood, Carol K. Kasper, P. B. A. Kernoff, Peter H. Levine, Jeanne M. Lusher, Pier Mannuccio Mannucci, I. Scharrer, Mary A. MacKenzie, N Pancham, H Kuo, Randy Allred	1990	185
5	Recombinant Factor VIII for the Treatment of Previously Untreated Patients with Hemophilia A Survey of Anesthesiology ·Jeanne M. Lusher, Steven Arkin, C. F. ABILGAARD, Richard S. Schwartz	1993	168
6	Loss of high‐responder inhibitors in patients with severe hemophilia A and human immunodeficiency virus type 1 infection: A report from the multi‐center hemophilia cohort study American Journal of Hematology ·G. L. Bray, Barbara L. Kroner, Steven Arkin, L. W. Aledort, MW Hilgartner, M. Elaine Eyster, M. V. Ragni, J. J. Goedert	1993	99
7	Clinical evaluation of moroctocog alfa (AF‐CC), a new generation of B‐domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full‐length recombinant factor VIII Haemophilia ·Michael Recht, László Nemes, Michał Matysiak, Marilyn J. Manco‐Johnson, Jeanne M. Lusher, Mark P. Smith, P.M. Mannucci, C. R. M. Hay, Thomas C. Abshire, Amanda C. O’Brien, Brooke Hayward, Chandrasekhar Udata, David A. Roth, Steven Arkin	2009	67
8	Effects of stathmin inhibition on the mitotic spindle Journal of Cell Science ·Camelia Iancu, Sucharita J. Mistry, Steven Arkin, Sylvan Wallenstein, George F. Atweh	2001	64
9	Expression of intercellular adhesion molecule-1 (CD54) on hematopoietic progenitors Blood ·Steven Arkin, B Naprstek, L Guarini, Soldano Ferrone, Lipton Jm	1991	63
10	Human recombinant DNA-derived antihemophilic factor in the treatment of previously untreated patients with hemophilia A: final report on a hallmark clinical investigation Journal of Thrombosis and Haemostasis ·Jeanne M. Lusher, C F Abildgaard, Steven Arkin, Pier Mannuccio Mannucci, R. Zimmermann, Lawrence A. Schwartz, Deborah Hurst	2004	61
11	A first‐in‐human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of PF‐06741086, an anti‐tissue factor pathway inhibitor mAb, in healthy volunteers Journal of Thrombosis and Haemostasis ·Matthew Cardinal, Constantino Kantaridis, Tong Zhu, Pengtao Sun, Debra D. Pittman, John E. Murphy, Steven Arkin	2018	60
12	Activated Recombinant Human Coagulation Factor VII Therapy for Intracranial Hemorrhage in Patients with Hemophilia A or B with Inhibitors Pathophysiology of Haemostasis and Thrombosis ·Steven Arkin, Herbert Cooper, J. Hutter, S. Miller, M Schmidt, Nita L. Seibel, Amy D. Shapiro, Indira Warrier	1998	60
13	Bosutinib versus Placebo for Autosomal Dominant Polycystic Kidney Disease Journal of the American Society of Nephrology ·Vladimı́r Tesař, Kazimierz Ciechanowski, York Pei, Irina Barash, Megan B. Shannon, Ray Li, Jason H. Williams, Matteo Levisetti, Steven Arkin, Andreas L. Serra	2017	59
14	An intrinsic progenitor defect in Diamond‐Blackfan anaemia British Journal of Haematology ·Philip H. Tsai, Steven Arkin, Jeffrey M. Lipton	1989	58
15	Taxol and anti-stathmin therapy: a synergistic combination that targets the mitotic spindle. PubMed ·Camelia Iancu, Sucharita J. Mistry, Steven Arkin, George F. Atweh	2000	56
16	Human coagulation factor FVIIa (recombinant) in the management of limb-threatening bleeds unresponsive to alternative therapies: results from the NovoSeven emergency-use programme in patients with severe haemophilia or with acquired inhibitors. PubMed ·Steven Arkin, Francine Blei, James Fetten, R. S. Foulke, Gerald S. Gilchrist, Margaret A. Heisel, Nigel S. Key, C. Thomas Kisker, (unknown), Frank Shafer, Prabodh Shah, Donald K. Strickland	2000	55
17	Efficacy and Safety of Bosutinib (SKI-606) in Patients with Chronic Phase (CP) Ph+ Chronic Myelogenous Leukemia (CML) with Resistance or Intolerance to Imatinib. Blood ·Jörge E. Cortes, Hagop M. Kantarjian, Dong Wook Kim, H. Jean Khoury, Anna Turkina, Zhixiang Shen, Tim H. Brümmendorf, Mammen Chandy, Steven Arkin, Carlo Gambacorti‐Passerini	2008	43
18	Long‐term safety and efficacy of the anti‐tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: Phase II study results British Journal of Haematology ·Johnny Mahlangu, José Luis Lamas, Juan Cristóbal Morales, Daniel R Malan, John G. Teeter, Robert J Charnigo, Eunhee Hwang, Steven Arkin	2022	43
19	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Domagrozumab (PF‐06252616), an Antimyostatin Monoclonal Antibody, in Healthy Subjects Clinical Pharmacology in Drug Development ·Indranil Bhattacharya, Sylvester Pawlak, Shannon Marraffino, Jared Christensen, Sarah P. Sherlock, Christine Alvey, Carl Morris, Steven Arkin, Michael Binks	2017	42
20	B‐domain deleted recombinant factor VIII preparations are bioequivalent to a monoclonal antibody purified plasma‐derived factor VIII concentrate: a randomized, three‐way crossover study Haemophilia ·C. M. Kessler, Joan Cox Gill, G C White, A. M. James Shapiro, Steven Arkin, David A. Roth, Xiang Guang Meng, Jeanne M. Lusher	2005	41

About Steven Arkin

Steven Arkin is a scholar working on Hematology, Genetics, Virology, Cardiology and Cardiovascular Medicine and Immunology, having authored 53 papers that have together received 2.5k indexed citations. Recurring topics across this work include Hemophilia Treatment and Research (30 papers), Chronic Myeloid Leukemia Treatments (11 papers), Blood Coagulation and Thrombosis Mechanisms (10 papers), Platelet Disorders and Treatments (9 papers), Chronic Lymphocytic Leukemia Research (7 papers), Atrial Fibrillation Management and Outcomes (5 papers), Coagulation, Bradykinin, Polyphosphates, and Angioedema (4 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). The work is most often cited by research in Hematology (1.7k citations), Genetics (693 citations), Rheumatology (220 citations), Immunology (258 citations) and Oncology (301 citations). Steven Arkin has collaborated with scholars based in United States, Italy and Poland. Frequent co-authors include Jeanne M. Lusher, Richard S. Schwartz, Charles F. Abildgaard, Jörge E. Cortes, Carlo Gambacorti‐Passerini, H. Jean Khoury, Hagop M. Kantarjian, Anna Turkina, Tim H. Brümmendorf and George F. Atweh. Their work appears in journals such as Blood, Haemophilia, Journal of Thrombosis and Haemostasis, British Journal of Haematology and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact